Published 22 October 2008, doi:10.1136/bmj.a2209
Cite this as: BMJ 2008;337:a2209

News

Atorvastatin advertising misled over benefits for women, study claims

Roger Dobson

1 Abergavenny

The first 150 words of the full text of this article appear below.

Advertising of the world’s best selling drug failed to disclose the absence of benefits for women, who should be entitled to compensation to recoup the costs of treatment, claim experts in epidemiology and law in a new analysis.

They argue that unqualified claims of protection against heart attacks made in advertisements for the lipid lowering drug atorvastatin (which is made by Pfizer and sold as Lipitor) may be misleading and that the advertising raises concerns about the way the US Food and Drug Administration regulates drugs (Journal of Empirical Legal Studies 2008;5:507-50, doi:10.1111/j.1740-1461.2008.00132.x)

The authors, Theodore Eisenberg, a professor of law at Cornell Law School, and Martin Wells, professor of clinical epidemiology at Cornell University Weill Medical College, claim that a substantial portion of the multibillion dollar market in statins may be made up of users for whom the drugs offer no benefit.

They add that remedies . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Access jobs at BMJ Careers
Whats new online at Student BMJ